Therapy Of XDR TB with thioridazine a drug beyond patent protection but eligible for patent “as new use”

Authors: Amaral L, Molnar J
Journal: Recent Patents on Anti-Infective Drug Discovery
Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Therapy+of+XDR-TB+with+thioridazine+a+drug+beyond+patent+protection+but+eligible+for+patent+%E2%80%9Cas+new+use

Mycobacterium tuberculosis that is resistant to Isoniazid (INH) and Rifampin (Rif) and hence, multi-drug resistant (MDR) has progressed to extensive drug resistant (XDR) status. XDR strains of Mycobacterium tuberculosis (XDR Mtb) are resistant, in addition to INH and Rif, to any fluoroquinolone, streptomycin and to any of the injectable anti-TB drugs kanamycin, amikacin and capreomycin.
Read More

Clinical relevance of multiple single-nucleotide polymorphisms in Pneumocystis jirovecii pneumonia: development of a multiplex PCR-single-base-extension.

Authors: Amaral L, Dastidar SG, Dutta NK, Karakousis PC, Mazumdar K
Journal: Recent Patents on Anti-Infective Drug Discovery
Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=New+patentable+use+of+an+old+neuroleptic+compound+thioridazine+to+combat+tuberculosis%3A+a+gene+regulation+perspective

Use of the old antipsychotic phenothiazine thioridazine (THZ) for therapy of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) infection is now being seriously considered.
Read More

Targeting the human macrophage with combinations of drugs and inhibitors of Ca2+ and K+ transport to enhance the killing of intracellular multi-drug resistant Mycobacterium tuberculosis (MDR-TB)–a novel, patentable approach to limit the emergence of XDR-TB.

The emergence of resistance in tuberculosis has become a serious problem for the control of this disease. For that reason, new therapeutic strategies that can be implemented in the clinical setting are urgently needed.
Read More

New patentable use of an old neuroleptic compound thioridazine to combat tuberculosis: a gene regulation perspective.

Authors: Amaral L, Dastidar SG, Dutta NK, Karakousis PC, Mazumdar K
Journal: Recent Patents on Anti-Infective Drug Discovery
Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=New+patentable+use+of+an+old+neuroleptic+compound+thioridazine+to+combat+tuberculosis%3A+a+gene+regulation+perspective

Inhibition of drug efflux in mycobacteria with phenothiazines and other putative efflux inhibitors.

Authors: Ainsa JA, Amaral L, Rodrigues L, Viveiros M
Journal: Recent Patents on Anti-Infective Drug Discovery
Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Inhibition+of+drug+efflux+in+mycobacteria+with+phenothiazines+and+other+putative+efflux+inhibitors

Mycobacteria are responsible for some of the oldest diseases known to man, usually associated with high morbility and mortality rates. An example is tuberculosis (TB), a major public health problem that accounts for eight million new cases each year.
Read More

Therapy Of XDR TB with thioridazine a drug beyond patent protection but eligible for patent “as new use”

Clinical relevance of multiple single-nucleotide polymorphisms in Pneumocystis jirovecii pneumonia: development of a multiplex PCR-single-base-extension.

Targeting the human macrophage with combinations of drugs and inhibitors of Ca2+ and K+ transport to enhance the killing of intracellular multi-drug resistant Mycobacterium tuberculosis (MDR-TB)–a novel, patentable approach to limit the emergence of XDR-TB.

New patentable use of an old neuroleptic compound thioridazine to combat tuberculosis: a gene regulation perspective.

Inhibition of drug efflux in mycobacteria with phenothiazines and other putative efflux inhibitors.

About GHTM

Contacts

Map